Nanotechnology versus other techniques in improving drug dissolution

Current Pharmaceutical Design

Volumn 20, Issue 3, 2014, Pages 474-482

  Kwok, Philip Chi Lip ^a   Chan, Hak Kim ^b  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Agglomeration; Complexation; Dissolution rate; Nanoparticles; Nanosuspension; Prodrug; Salt form; Solubility; Stability; Surface area

Indexed keywords

BIOLOGICAL AVAILABILITY; CHEMICAL PRECIPITATION; CHEMISTRY, PHARMACEUTICAL; CRYSTALLIZATION; DRUG STABILITY; MODELS, CHEMICAL; NANOPARTICLES; NANOTECHNOLOGY; PARTICLE SIZE; PHARMACEUTICAL PREPARATIONS; PLANT PREPARATIONS; SOLUBILITY; SURFACE PROPERTIES; TECHNOLOGY, PHARMACEUTICAL;

EID: 84894039187     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990400     Document Type: Article

References (98)

1. Yu LX, Amidon GL, Polli JE, et al. Biopharmaceutics classification system: The scientific basis for biowaiver extensions. Pharm Res 2002; 19: 921-5.
2. Müller RH, Junghanns JUAH. Drug nanocrystals/naosuspensions for the delivery of poorly soluble drugs. In: Torchilin, V. P. Ed, Nanoparticulates as Drug Carriers. London, Imperial College Press. 2006.
3. Gelperina S, Kisich K, Iseman MD, Heifets L. The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis. Am J Respir Crit Care Med 2005; 172: 1487-90.
4. Dokoumetzidis A, Macheras P. A century of dissolution research: From Noyes and Whitney to the Biopharmaceutics Classification System. Int J Pharm 2006; 321: 1-11.
5. José-Yacamán M, Gutierrez-Wing C, Miki M, Yang DQ, Piyakis KN ES. Surface diffusion and coalescence of mobile metal nanoparticles. J Physical Chem B 2005; 109: 9703-11.
6. Gupta RB. Fundamentals of drug nanoparticles. In: Gupta, R. B.; Kompella, U. B. Ed, Nanoparticle Technology for Drug Delivery. New York, NY, Taylor and Francis Group 2006.
7. Heng D, Cutler DJ, Chan HK, Yun J, Raper JA. Dissolution kinetic behavior of drug nanoparticles and their conformity to the diffusion model. Langmuir 2008; 24: 7538-44.
8. Cheow WS, Hadinoto K. Self-assembled amorphous drugpolyelectrolyte nanoparticle complex with enhanced dissolution rate and saturation solubility. J Colloid Interface Sci 2012; 367: 518-26.
9. Hancock BC, Parks M. What is the true solubility advantage for amorphous pharmaceuticals? Pharm Res 2000; 17: 397-404.
10. Murdande SB, Pikal MJ, Shankar RM, Bogner RH. Solubility advantage of amorphous pharmaceuticals: I. A thermodynamic analysis. J Pharm Sci 2010; 99: 1254-64.
11. Murdande SB, Pikal MJ, Shankar RM, Bogner RH. Solubility advantage of amorphous pharmaceuticals: II. Application of quantitative thermodynamic relationships for prediction of solubility enhancement in structurally diverse insoluble pharmaceuticals. Pharm Res 2010; 27: 2704-14.
12. Thombre AG, Shah JC, Sagawa K, Caldwell WB. In vitro and in vivo characterization of amorphous, nanocrystalline, and crystalline ziprasidone formulations. Int J Pharm 2012; 428: 8-17.
13. Merisko-Liversidge E, Liversidge GG. Nanosizing for oral and parenteral drug delivery: A perspective on formulating poorlywater soluble compounds using wet media milling technology. Adv Drug Delivery Rev 2011; 63: 427-40.
14. Merisko-Liversidge, E, Liversidge, GG. Drug nanoparticles: Formulating poorly water-soluble compounds. Toxicol Pathol 2008; 36: 43-8.
15. Merisko-Liversidge E, Liversidge GG, Cooper ER. Nanosizing: A formulation approach for poorly-water-soluble compounds. Eur J Pharm Sci 2003; 18: 113-20.
16. Junghanns J-UAH, Müller RH. Nanocrystal technology, drug delivery and clinical applications. International J Nanomed 2008; 3: 295-309.
17. Keck CM, Müller RH. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. Eur J Pharm Sci 2006; 62: 3-16.
18. Van Eerdenbrugh B, Vercruysse S, Martens JA, et al. Microcrystalline cellulose, a useful alternative for sucrose as a matrix former during freeze-drying of drug nanosuspensions-A case study with itraconazole. Eur J Pharm Biopharm 2008; 70: 590-6.
19. Chan HK, Kwok PCL. Production methods for nanodrug particles using the bottom-up approach. Adv Drug Delivery Rev 2011; 63: 406-16.
20. Chiou H, Chan HK, Heng D, Prud'homme RK, Raper JA. A novel production method for inhalable cyclosporine A powders by confined liquid impinging jet precipitation. J Aerosol Sci 2008; 39: 500-9.
21. Müller RH, Möschwitzer J, Bushrab FN. Manufacturing of nanoparticles by milling and homogenization techniques. In: Gupta, R. B.; Kompella, U. B. Ed, Nanoparticle Technology for Drug Delivery. New York, NY, Taylor and Francis Group 2006.
22. Yamasaki K, Kwok PCL, Fukushige K, Prud'homme RK, Chan HK. Enhanced dissolution of inhalable cyclosporine nano-matrix particles with mannitol as matrix former. Int J Pharm 2011; 420: 34-42.
23. Hu T, Chiou H, Chan HK, Chen JF, Yun J. Preparation of inhalable salbutamol sulphate using reactive high gravity controlled precipitation. J Pharm Sci 2008; 97: 944-9.
24. Chang PC, Mou CY, Lee DJ. Micromixing and macromixing effects in unsteady chemical reaction system. J Physical Chem A 1999; 103: 5485-9.
25. Chen JF, Zhou MY, Shao L, et al. Feasibility of preparing nanodrugs by high-gravity reactive precipitation. Int J Pharm 2004; 269: 267-74.
26. Chen JF, Wang YH, F G, Wang XM, Zheng C. Synthesis of nanoparticles with novel technology: High gravity reactive precipitation. Ind Eng Chem Res 2000; 39: 948-54.
27. Hu TT, Wang JX, Shen ZG, Chen JF. Engineering of drug nanoparticles by HGCP for pharmaceutical applications. Particuology 2008; 6: 239-51.
28. Chiou H, Chan HK, Prud'homme RK, Raper JA. Evaluation on the use of confined liquid impinging jets fot the synthesis of nanodrug particles. Drug Development Ind Pharm 2008; 34: 59-64.
29. Kumar V, Adamson DH, Prud'homme RK. Fluorescent polymeric nanoparticles: Aggregation and phase behavior of pyrene and amphotericin B molecules into nanoparticle cores. Small 2010; 6: 2907-14.
30. Chen T, D'Addio SM, Kennedy MT, et al. Protected peptide nanoparticles: Experiments and brownian dynamics simulations of the energetics of assembly. Nano Letters 2009; 9: 2218-22.
31. Gindy ME, Panagiotopoulos AZ, Prud'homme RK. Composite block copolymer stabilized nanoparticles: Simultaneous encapsulation of organic actives and inorganic nanostructures. Langmuir 2008; 24: 83-90.
32. Liu Y, Cheng C, Liu Y, Prud'homme RK, Fox RO. Mixing in a multi-inlet vortex mixer (MIVM) for flash nano-precipitation. Chem Eng Sci 2008; 63: 2829-42.
33. Zhu B, Kwok PCL, Prud'homme RK, Traini D, Chan HK, Young PM. The use of quad-impinging jet technology for the production of pharmaceutical nanoparticles. Formula VI Abstracts 2010: PD P10.
34. Reverchon E, De Marco I, Torino E. Nanoparticles production by supercritical antisolvent precipitation: A general interpretation. J Supercritical Fluids 2007; 43: 126-38.
35. Foster NR, Sih R. Development of a novel precipitation technique for the production of highly repirable powders: The atomized rapid injection for solvent extraction process. In: Hutchenson, K. W.; Scurto, A. M.; Subramaniam, B. Ed, Gas-Expanded Liquids and Near-Critical Media. Washington DC, Am Chem Soc 2009; pp: 309-47.
36. Foster NR, Sih, RPT Particle formation. US 2010/0144670, 2010.
37. Dhumal RS, Biradar SV, Yamamura S, Paradkar AR, York P. Preparationof amorphous cefuroxime axetil nanoparticles by sonoprecipitation for enhancement of bioavailability. European J Pharmaceutics and Biopharmaceutics 2008; 70: 109-15.
38. Chen JF, Zhang JY, Shen Z-G, Zhong J, Yun J. Preparation and characterization of amorphous cefuroxime axetil drug nanoparticles with novel technology: High-gravity antisolvent precipitation. Ind Eng Chem Res 2006; 45: 8723-7.
39. Wang GL, Wang JX, Shen ZG, Guo F, Chen JF, Yun J. Preparation of azithromycin ultrafine particles with reactive precipitation. Chinese J Process Engineering 2007; 7: 802-6.
40. Chiou H, Li L, Hu T, Chan HK, Chen JF, Yun J. Production of salbutamol sulfate for inhalation by high-gravity controlled antisolvent precipitation. Int J Pharm 2007; 331: 93-8.
41. Zhao H, Wang JX, Wang QA, Chen JF, Yun J. Controlled liquid antisolvent precipitation of hydrophobic pharmaceutical nanoparticles in a microchannel reactor. Ind Eng Chem Res 2007; 46: 8229-35.
42. Schmid K, Arpagaus C, Friess W. Evaluation of the Nano Spray Dryer B-90 for pharmaceutical applications. Pharm Development Technol 2011; 16: 287-94.
43. Lee SH, Heng D, Ng HK, Chan HK, Tan RBH. Nano spray drying: a novel method for preparing protein nanoparticles for protein therapy. Int J Pharm 2011; 403: 192-200.
44. Eerikäinen H, Watanabe W, Kauppinen EI, Ahonen PP. Aerosol flow reactor method for synthesis of drug nanoparticles. Eur J Pharm Biopharm 2003; 55: 357-60.
45. Watanabe W, Ahonen P, Kauppinen E, et al. Inhalation particles. WO 01/49263, 2001.
46. Watanabe WS, Kauppinen EI, Ahonen PP, Brown DP, Muttonen E. Novel method for the synthesis of inhalable multicomponent drug powders with controlled morphology and size. In: Dalby, R. N.; Byron, P. R.; Peart, J.; Farr, S. J. Ed, Respiratory Drug Delivery VIII. Raleigh, NC, Davis Horwood International 2002; pp 795-8.
47. Chan H-K, Gonda I. Respirable form of crystals of cromoglycic acid. J Pharm Sci 1989; 78: 176-80.
48. Chan H-K, Gonda I. Aerodynamic properties of elongated particles of cromoglycic acid. J Aerosol Sci 1989; 20: 157-68.
49. Chen D-R, Pui DYH, Kaufman SL. Electrospraying of conducting liquids for monodisperse aerosol generation in the 4 nm to 1.8 μm diameter range. J Aerosol Sci 1995; 26: 963-77.
50. Gomez A, Bingham D, de Juan L, Tang K. Production of protein nanoparticles by electrospray drying. J Aerosol Sci 1998; 29: 561-74.
51. Wu L, Zhang J, Watanabe W. Physical and chemical stability of drug nanoparticles. Adv Drug Delivery Rev 2011; 63: 456-69.
52. Van Eerdenbrugh B, Van den Mooter G, Augustijns P. Top-down production of drug nanocrystals: Nanosuspension stabilization, miniaturization and transformation into solid products. Int J Pharm 2008; 364: 64-75.
53. Jacobs C, Müller RH. Production and characterization of a budesonide nanosuspension for pulmonary administration. Pharm Res 2002; 19: 189-94.
54. List M, Sucker H. Pharmaceutical collodial hydrosols for injection. GB 2200048, 1988.
55. Shekunov BY, Chattopadhyay P, Seitzinger J, Huff R. Nanoparticles of poorly water-soluble drugs prepared by supercritical fluid extraction of emulsions. Pharm Res 2006; 23: 196-204.
56. Lennart L, Skantze P, Skantze U, Westergren J, Olsson U. Amorphous drug nanosuspensions. 3. Particle dissolution and crystal growth. Langmuir 2007; 23: 9866-74.
57. Ali HSM, York P, Blagden N. Preparation of hydrocortisone nanosuspension through a bottom-up nanoprecipitation technique using microfluidic reactors. Int J Pharm 2009; 375: 107-13.
58. Zhang X, Xia Q, Gu N. Preparation of all-trans retinoic acid nanosuspensions using a modified precipitation method. Drug Development Ind Pharm 2006; 32: 857-63.
59. Lai F, Sinico C, Ennas G, Marongiu F, Marongiu G, Fadda AM. Diclofenac nanosuspensions: Influence of preparation procedure and crystal form on drug dissolution behaviour. Int J Pharm 2009; 373: 124-32.
60. Chaubal MV, Popescu C. Conversion of nanosuspensions into dry powders by spray drying: A case study. Pharm Res 2008; 25: 2302-8.
61. Van Eerdenbrugh B, Froyen L, Van Humbeck J, Martens JA, Augustijns P, Van den Mooter G. Drying crystalline drug nanosuspensions-The importance of surface hydrophobicity on dissolution behavior upon redispersion. Eur J Pharm Sci 2008; 35: 127-35.
62. Pace S, Pace GW, Parikh I, Misra A. Novel injectable formulations of insoluble drugs. Pharm Technol 1999; 23: 116-34.
63. Abdelwahed W, Degobert G, Stainmesse S, Fessi H. Freeze-drying of nanoparticles: formulation, process and storage considerations. Adv Drug Deliv Rev 2006; 58: 1688-713.
64. Cheow WS, Ng MLL, Kho K, Hadinoto K. Spray-freeze-drying production of thermally sensitive polymeric nanoparticle aggregates for inhaled drug delivery: Effect of freeze-drying adjuvants. Int J Pharm 2011; 404: 289-300.
65. Wang Y, Kho K, Cheow WS, Hadinoto K. A comparison between spray drying and spray freeze drying for dry powder inhaler formulation of drug-loaded lipid-polymer hybrid nanoparticles. Int J Pharm IN PRESS.
66. Kho K, Hadinoto K. Optimizing aerosolization efficiency of drypowder aggregates of thermally-sensitive polymeric nanoparticles produced by spray-freeze-drying. Powder Technol 2011; 214: 169-76.
67. Basa S, Muniyappan T, Karatgi P, Prabhu R, Pillai R. Production and in vitro characterization of solid dosage form incorporating drug nanoparticles. Drug Development Ind Pharm 2008; 34: 1209-18.
68. Heng D, Cutler DJ, Chan HK, Yun J, Raper JA. What is a suitable dissolution method for drug nanoparticles? Pharm Res 2008; 25: 1696-701.
69. Van Eerdenbrugh B, Froyen L, Van Humbeck J, Martens JA, Augustijns P, Van Den Mooter G. Alternative matrix formers for nanosuspension solidification: Dissolution performance and X-ray microanalysis as an evaluation tool for powder dispersion. Eur J Pharm Sci 2008; 35: 344-53.
70. Gassman P, Sucker H Improvements in pharmaceutical compositions. WO 92/18105, 1992.
71. Van Eerdenbrugh B, Froyen L, Martens JA, et al. Characterization of physico-chemical properties and pharmaceutical performance of sucrose co-freeze-dried solid nanoparticulate powders of the anti-HIV agent loviride prepared by media milling. Int J Pharm 2007; 338: 198-206.
72. Mukerjee A, Vishwanatha JK. Formulation, characterization and evaluation of curcumin-loaded PLGA nanospheres for cancer therapy. Anticancer Res 2009; 29: 3867-76.
73. Yen FL, Wu TH, Tzeng CW, Lin LT, Lin CC. Curcumin nanoparticles improve the physicochemical properties of curcumin and effectively enhances its antioxidant and antihepatoma activities. J Agricultural Food Chem 2010; 58: 7376-82.
74. Chen Y, Lin X, Park H, Greever R. Study of artemisinin nanocapsules as anticancer drug delivery systems. Nanomedicine: Nanotechnol Biol Med 2009; 5: 316-22.
75. Min KH, Park K, Kim YS, et al. Hydrophobically modified glycol chitosan nanoparticles-encapsulated camptothecin enhance the drug stability and tumor targeting in cancer therapy. J Controlled Release 2008; 127: 208-18.
76. Singh A, Duggal S, Kaur N, Singh J. Berberine Alkaloid with wide spectrum of pharmacological activities. J Natural Products 2010; 3: 64-75.
77. Lin A, Li H, Liu Y, Qiu X. Preparation and release characteristics of berberine chitosan nanoparticles in vitro. China Pharmacy 2007; 18: 755-7.
78. Finholt P. Influence of formulation on dissolution rate. In: Leeson, L. J.; Carstensen JT. Ed, Dissolution Technology. Washington DC, The Industrial Pharmaceutical Technology Section of the Academy of Pharmaceutical Science 1974; pp 106-46.
79. British Pharmacopoeia, The Stationary Office: London, 2012.
80. United States Pharmacopeia 32, United States Pharmacopeial Convention: Rockville, MD 2009.
81. Moller H, Wirbitzki E. Special cases of dissolution testing using the flow-through system. STP Pharma Sci 1990; 6: 657-62.
82. Langenbucher F, Benz D, Kurth W, Moller H, Otz M. Standardized flow-through method as an alternative to existing pharmacopoeial dissolution testing. Pharmazeutische Industrie 1989; 51: 1276-81.
83. Wennergren B, Lindberg J, Nicklasson M, et al. A collaborative in vitro dissolution study: Comparing the flow-through method with the USP paddle method using USP prednisone calibrator tablets. Int J Pharm 1989; 53: 35-41.
84. Nicklasson M, Orbe A, Lindberg J, et al. A collaborative study of the in vitro dissolution of phenacetin crystals comparing the flow through method with the USP paddle method. International J Pharmaceutics 1991; 69: 255-64.
85. Adams DH, Wood MJ, Farrell ID. Oral cefuroxime axetil: clinical pharmacology and comparative dose studies in urinary tract infection. J Antimicrobial Chemotherapy 1985; 16: 359-66.
86. Gowthamarajan K, Singh SK. Dissolution testing of poorly soluble drugs: A continuing perspective. Dissolution Technol 2010; 17: 24-32.
87. Sager TM, Porter DW, Robinson VA, Lindsley WG, Schwegler-Berry DEC, V. Improved method to disperse nanoparticles for in vitro and in vivo investigation of toxicity. Nanotoxicology 2007; 1: 118-29.
88. Heng D, Ogawa K, Cutler DJ, et al. Pure drug nanoparticles in tablets: What are the dissolution limitations? J Nanoparticle Res 2010; 12: 1743-54.
89. Neau SH. Pharmaceutical salts. In: Liu, R. Ed, Water-Insoluble Drug Formulation. Boca Raton, FL, CRC Press. 2008.
90. Gould PL. Salt selection for basic drugs. International J Pharmaceutics 1986; 33: 201-17.
91. Morris KR, Fakes MG, Thakur AB, et al. An integrated approach to the selection of optimal salt form for a new drug candidate. Int J Pharm 1994; 105: 209-17.
92. Stella VJ, Nti-Addae KW. Prodrug strategies to overcome poor water solubility. Adv Drug Delivery Rev 2007; 59: 677-94.
93. Scriba GKE. Phenytoin-lipid conjugates: Chemical, plasma esterase-mediated, and pancreatic lipase-mediated hydrolysis in vitro. Pharm Res 1993; 10: 1181-6.
94. Neau SH. Prodrugs for improved aqueous solubility. In: Liu, R. Ed, Water-Insoluble Drug Formulation. Boca Raton, FL, CRC Press. 2008.
95. Stella VJ, He Q. Cyclodextrins. Toxicologic Pathology 2008; 36: 30-42.
96. Loftsson T, Jarho P, Másson M, Järvinen T. Cyclodextrins in drug delivery. Exp Opinion Drug Delivery 2005; 2: 335-51.
97. Tong WQ, Wen H. Applications of complexation in the formulation of insoluble compounds. In: Liu, R. Ed, Water-Insoluble Drug Formulation. Boca Raton, FL, CRC Press 2008.
98. Marple VA, Roberts DL, Romay FJ, et al. Next Gereration Pharmaceutical Impactor (A new impactor for pharmaceutical inhaler testing). Part I: Design. J Aerosol Med 2003; 16: 283-99.